Liquid Biopsy Market to Grow at 13.1% CAGR, Revolutionizing Cancer Diagnostics

The global liquid biopsy market is projected to grow significantly, with an estimated value of USD 35.3 billion by 2033, up from USD 10.3 billion in 2023, reflecting a compound annual growth rate (CAGR) of 13.1% during the forecast period from 2023 to 2033. This growth is driven by several key factors, including the increasing prevalence of cancer, advancements in technology, and the rising adoption of non-invasive diagnostic methods.

One of the primary growth drivers is the increasing incidence of cancer worldwide, which has fueled the demand for less invasive and more accurate diagnostic tools like liquid biopsies. These tests offer a non-invasive alternative to traditional tissue biopsies, enabling the detection and monitoring of cancer through the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes in the blood. This technology is particularly advantageous for early cancer detection, monitoring treatment response, and detecting recurrence, thereby improving patient outcomes and reducing healthcare costs.

Technological advancements, such as the development of next-generation sequencing (NGS) and digital PCR systems, have significantly enhanced the sensitivity and accuracy of liquid biopsy tests. Companies like Illumina and Guardant Health are at the forefront of these innovations, offering advanced genomic profiling services and liquid biopsy panels that detect a wide range of mutations and biomarkers associated with various cancers​​.

However, the market faces several challenges, including reimbursement issues and the lack of insurance coverage for liquid biopsy tests in many regions. These financial barriers limit the adoption of these tests for early screening and routine monitoring, particularly in developing countries. Additionally, there is a need for more clinical validation and regulatory approvals to ensure the widespread adoption and acceptance of liquid biopsy technologies​.

Recent developments in the market include significant investments in research and development, strategic partnerships, and product launches. For instance, in 2023, companies like Tempus and Guardant Health launched new liquid biopsy tests designed for comprehensive genomic profiling and residual disease monitoring, respectively. These advancements are expected to further drive market growth by providing more precise and timely diagnostic options for cancer patients.

Overall, the liquid biopsy market is poised for substantial growth, driven by the increasing need for non-invasive diagnostic tools, continuous technological advancements, and the rising prevalence of cancer. However, addressing the challenges related to reimbursement and regulatory approvals will be crucial for maximizing the market’s potential

Key Takeaways

• The Liquid Biopsy Market was valued at approximately USD 10.3 billion in 2023, expected to reach around USD 35.3 billion by 2033.
• The market is experiencing a CAGR of 13.1% from 2023 to 2033, indicating robust growth.
• In 2023, Multi-Gene-Parallel Analysis (NGS) contributed 72.8% of the market revenue.
• Circular Nucleic Acids accounted for over 34.78% of the global revenue in 2023.
• Instruments held a dominant market share of 44.9% in 2023.
• Cancer detection through liquid biopsy comprised over 77% of the market share in 2023.
• Hospitals and laboratories controlled more than 47.2% of the market in 2023.
• North America led the market, generating over 47.1% of global revenues in 2023.
• In 2021, 235,760 Americans were diagnosed with non-small cell lung disease.
• The lifetime risk of lung cancer is 1 in 17 for men and 1 in 15 for women.
• In 2020, there were approximately 19.3 million new cancer cases and 10 million cancer deaths worldwide.
• Breast cancer has become the most prevalent type of cancer globally due to rising cases among women.
• The NBCCEDP assisted over 260,000 women with breast cancer screening in 2020.
• BioMark Diagnostics Solutions Inc. received US$825,000 for advancing its lung cancer liquid biopsy method.
• Emerging markets like India, China, South Korea, and Brazil offer significant growth opportunities for liquid biopsy.

Get Sample PDF Report: https://market.us/report/liquid-biopsy-market/request-sample/

Liquid Biopsy Market Key Segments

Product Type

• Instruments
• Consumables Kits and Reagents
• Software and Services

Biomarker Type

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles (EVs)
• Other Biomarker Types

Technology

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

Application

• Cancer
• Lung Cancer
• Prostate Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Gastrointestinal Cancer
• Others
• Reproductive Health
• Other Applications

End-use

• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers
• Other End-Uses

Clinical Application

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Other Clinical Applications

Key Regions

• North America (The US, Canada, Mexico)
• Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
• Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
• APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
• Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
• Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)

Buy Directly: https://market.us/purchase-report/?report_id=28756

Key Players Analysis

ANGLE plc is a prominent player in the liquid biopsy sector, specializing in the capture and analysis of circulating tumor cells (CTCs) through its proprietary Parsortix system. This technology allows for non-invasive cancer diagnostics and monitoring by capturing CTCs from blood samples. The Parsortix system is particularly noted for its ability to handle small sample volumes and maintain cell integrity, making it suitable for various cancer types. ANGLE’s innovations in liquid biopsy aim to enhance early detection and personalized treatment, driving its growth and influence in the market​.

Oncimmune focuses on developing and commercializing advanced diagnostics for early cancer detection and monitoring. Its EarlyCDT platform uses autoantibodies as biomarkers to detect cancer at its earliest stages, improving patient outcomes through timely intervention. The platform is designed to work with blood samples, providing a non-invasive and highly accurate method for cancer diagnosis. Oncimmune’s contributions to the liquid biopsy market emphasize the importance of early detection and the role of autoantibodies in identifying various cancer types​​.

Guardant Health Inc. is a leader in precision oncology, utilizing liquid biopsy to transform cancer care through its Guardant360 and GuardantOMNI tests. These tests analyze circulating tumor DNA (ctDNA) to provide comprehensive genomic profiles, guiding treatment decisions and monitoring disease progression. Guardant Health’s innovative approach allows for the detection of minimal residual disease and the emergence of resistance mutations, making it a critical player in the liquid biopsy market. The company continuously advances its technology to offer new insights into tumor biology and treatment efficacy​.

Myriad Genetics Inc. integrates genetic testing and molecular diagnostics into the liquid biopsy field, focusing on identifying hereditary cancer risks and guiding personalized treatment. Its myChoice CDx test assesses homologous recombination deficiency (HRD) in tumors, helping predict responses to PARP inhibitors. Myriad’s approach combines liquid biopsy with advanced genomic technologies to provide actionable insights for cancer treatment. The company’s robust pipeline and strategic partnerships aim to expand the utility of liquid biopsy in precision medicine​​.

Biocept Inc. specializes in developing liquid biopsy tests that detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in blood samples. The company’s Target Selector assays are designed to identify key genetic alterations and biomarkers associated with various cancers, aiding in treatment selection and monitoring. Biocept’s tests are widely used in clinical settings for their high sensitivity and specificity, offering a non-invasive alternative to traditional biopsy methods. The company’s focus on continuous innovation and expanding its test menu positions it strongly within the liquid biopsy market​​.

Liquid Biopsy Market Key Players:

• ANGLE plc
• Oncimmune
• Guardant Health Inc.
• Myriad Genetics Inc.
• Biocept Inc.
• Lucence Health Inc.
• Freenome Holdings Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Epigenomics AG
• Other Key Players

Liquid Biopsy Market Report Scope >> Market Value (2023): USD 10.3 Billion || Forecast Revenue (2033): USD 35.3 Billion || CAGR (2024-2033): 13.1% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.

Inquire More about report: https://market.us/report/liquid-biopsy-market/#inquiry

About Market.US

Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.

Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/

View More Trending Reports

AI In Breast Imaging Market Projected To Reach USD 14.01 billion By 2033, With CAGR Of 5.1%

AI In Remote Patient Monitoring Market Projected to reach USD 24.0 Billion with 26.6% CAGR By 2033

Asthma Treatment Market Will Increase USD 38.3 Billion By 2033 and Has Guessed around 3.9% CAGR

Asthma and COPD Drugs Market Set to Skyrocket, Reaching USD 64.6 Billion by 2033

Burn Care Market Expands, Predicted Value Soars to USD 6.17 Billion by 2033